About passage bio inc - PASG
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
PASG At a Glance
Passage Bio, Inc.
One Commerce Square
Philadelphia, Pennsylvania 19103
| Phone | 1-267-866-0311 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -45,522,000.00 | |
| Sector | Health Technology | Employees | 24 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PASG Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.003 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.357 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 1.585 |
PASG Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,896,750.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PASG Liquidity
| Current Ratio | 2.069 |
| Quick Ratio | 2.069 |
| Cash Ratio | 2.006 |
PASG Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -55.281 |
| Return on Equity | -113.782 |
| Return on Total Capital | -106.447 |
| Return on Invested Capital | -74.475 |
PASG Capital Structure
| Total Debt to Total Equity | 128.019 |
| Total Debt to Total Capital | 56.144 |
| Total Debt to Total Assets | 38.551 |
| Long-Term Debt to Equity | 109.00 |
| Long-Term Debt to Total Capital | 47.803 |